DENVER, Jan. 18, 2022 /PRNewswire/ -- DaVita Inc. today
announced its acquisition of transplant software company MedSleuth.
Working with transplant centers across the U.S., MedSleuth aims to
create greater connectivity among transplant candidates, transplant
centers, physicians and care teams to help improve the experience
and outcomes for kidney and liver transplant patients.
With this acquisition, DaVita deepens its efforts to fuel
transplant innovation, underscoring its commitment to improve care
at every stage and setting along a patient's kidney care
journey.
"Kidney transplantation is a life-changing option for most
people with kidney failure, one that's limited today by supply and
complexity," said Javier Rodriguez,
CEO for DaVita. "MedSleuth has built a powerful platform that can
help increase patients' access to transplantation. We're looking
forward to supporting the team to accelerate innovation and help
streamline the transplant process for transplant candidates,
transplant centers, physicians and care teams."
From lack of supply to meet the demand to understanding and
staying on top of the complex process from workup to wait list to
transplant, the U.S. transplant system can be complicated to
navigate.
MedSleuth's innovative software can help not only streamline the
process of evaluating candidates and keep them active on the
waitlist but may also help increase the rate of transplantation
through living donation. The software can also make it easier for
transplant candidates' doctors and care teams to help support them
along the transplant journey.
BREEZE™, MedSleuth's flagship product, helps remove certain
barriers for potential kidney and liver donors and recipients by
remotely gathering relevant clinical and demographic information
and sharing it with participating transplant centers—effectively
streamlining the transplant process, from candidate evaluation
through donor and recipient follow-up.
MATCHGRID™, MedSleuth's paired exchange platform, uses
optimization algorithms to find chains for paired donation. This
helps transplant center clinicians rapidly match living organ
donors with recipients who have willing, healthy but incompatible
donors.
"We knew DaVita was the best long-term home for MedSleuth
because we share a common vision to increase access to
transplantation," said James
Kalamas, CEO and founder of MedSleuth. "Together, we'll
continue reimagining the transplant experience to help improve the
lives of transplant patients."
Increasing access to transplantation is core to DaVita's focus
on health equity and go-forward strategy in value-based care
arrangements with the government and private health insurance
plans.
As a comprehensive kidney care provider, DaVita is helping break
down silos along the kidney care continuum—from chronic kidney
disease to end stage kidney disease through transplantation—to
improve the lives of kidney patients.
Kalamas will continue to lead the business, which will operate
as a wholly-owned subsidiary of DaVita Inc.
To learn more about MedSleuth, visit MedSleuth.com. To learn
more about DaVita, visit DaVita.com/About.
About DaVita Inc.
DaVita (NYSE: DVA) is a health
care provider focused on transforming care delivery to improve
quality of life for patients globally. The company is one of the
largest providers of kidney care services in the U.S. and has been
a leader in clinical quality and innovation for more than 20 years.
DaVita cares for patients at every stage and setting along their
kidney health journey—from slowing the progression of kidney
disease to helping to support transplantation, from acute hospital
care to dialysis at home. As of September 30, 2021, DaVita
served 203,000 patients at 2,822 outpatient dialysis centers
in the United States. The company also operated 333
outpatient dialysis centers in ten countries worldwide. DaVita has
reduced hospitalizations, improved mortality, and worked
collaboratively to propel the kidney care industry to adopt an
equitable and high-quality standard of care for all patients,
everywhere. To learn more, visit DaVita.com/About.
Forward-Looking Statements
Certain statements
in this press release are forward-looking statements that are
subject to risks and uncertainties. These forward-looking
statements are based on management's current expectations. Various
important factors could cause actual results to differ materially
from these forward-looking statements, including the risks
identified in our U.S. Securities and Exchange Commission filings.
DaVita disclaims any obligation to update any forward-looking
statement contained in this press release, except as may be
otherwise required by law.
Contact Information
Media:
Ashley Henson
ashley.henson@davita.com
(303) 876-6626
View original content to download
multimedia:https://www.prnewswire.com/news-releases/davita-acquires-medsleuth-deepens-efforts-to-improve-transplant-experience-301462227.html
SOURCE DaVita Inc.